Download presentation
Presentation is loading. Please wait.
1
RMTC Anabolic Steroid Studies
Richard Sams, PhD Florida Racing Laboratory University of Florida and Scott D. Stanley, PhD Kenneth L. Maddy Equine Chemistry Laboratory University of California at Davis
2
Objectives Characterize plasma concentrations of the anabolic steroids in exercised Thoroughbred horses (geldings and mares) of racing age after administration of race track or label dose commercial and compounded formulation in a sufficient number of animals to obtain statistically meaningful results.
3
Why study plasma? Subject to less variability than urine concentrations Easier to perform assay on plasma than urine Anabolic steroids are detectable in plasma by modern LC-MS methods for clinically relevant periods Anabolic steroids are excreted in urine as metabolites or mixtures of metabolites that more require extensive sample preparation.
4
Responsibilities for RMTC Studies
Protocols for AAS studies Developed by working advisory group including Drs. Walter Hyde, Scott Stanley, Lawrence Soma, and Richard Sams Drug administrations and sample collections conducted under the direction of Dr. Patrick Colahan at the Florida Equine Performance Laboratory at the University of Florida Sample analyses conducted under the direction of Dr. Richard Sams at the Florida Racing Laboratory at the University of Florida and Dr. Scott Stanley at the Kenneth L. Maddy Equine Analytical Chemistry Laboratory at the University of California at Davis
5
General Description of Studies
Experimental animals Thoroughbred horses (geldings and mares; aged 3-10 years) that are subjected to a conditioning regimen on a treadmill Source of AAS purchased from commercial sources or a compounding pharmacy Dose administered at the label dose for horses or at a commonly used race track dose Dosing regimen administered once IM or subcutaneously Sample Collection schedule Blood and urine samples were collected from each horse according to a pre-determined schedule. Samples were collected until the AAS was no longer detectable in two successive blood samples
6
General Description of Studies
Plasma AAS concentrations determined by liquid chromatographic-mass spectrometric methods developed and validated in the two analytical laboratories. Plasma concentrations from the two laboratories are being compared and differences, if any, investigated. Plasma threshold concentrations corresponding to the “95/95 tolerance limit” are being calculated by standard methods. Urine concentrations to be determined later relationships between plasma and urine concentrations to be investigated.
7
RMTC Stanozolol Study Formulation Source Dose Subjects
Aqueous suspension Source Frank’s Pharmacy, Ocala Florida Compounded product – Winstrol® is not available Dose 0.55 mg/kg IM Subjects 26 Thoroughbred horses
8
RMTC Stanozolol Study Method Sample collections LC-MS
Validated at UF and UCD laboratories Linear LOQ = 25 pg/mL LOD ~10 pg/mL Sample collections Stopped at 63 days Plasma concentrations below LOD for 2 successive collections Plasma concentration above LOD at 49 days
14
RMTC Testosterone Study
Formulation Aqueous suspension Source Frank’s Pharmacy, Ocala Florida Compounded product Dose 0.15 mg/kg subcutaneously Subjects 20 Thoroughbred horses
15
RMTC Testosterone Study
Method LC-MS Validated at UF and UCD laboratories Linear LOQ = 25 pg/mL LOD ~10 pg/mL Sample collections Stopped at 34 days Plasma concentrations below LOD for 2 successive collections Plasma concentration less than LOQ at 28 days
21
RMTC Boldenone Study Formulation Source Dose Subjects
boldenone undecylenate in oil (Equipoise®) Source Fort Dodge, Manhattan, Kansas Dose 1.1 mg/kg IM Subjects 20 Thoroughbred horses
22
RMTC Boldenone Study Method Sample Collections LC-MS
Validated at UF and UCD laboratories Linear LOQ = 25 pg/mL LOD ~10 pg/mL Sample Collections Stopped at 164 days Plasma concentrations below LOD for 2 successive collections Plasma concentration less than LOQ at 140 days
28
RMTC Nandrolone Study Formulation Source Dose Subjects
nandrolone decanoate in oil Source Frank’s Pharmacy, Ocala, Florida Dose 0.55 mg/kg IM Subjects 20 Thoroughbred horses
29
RMTC Nandrolone Study Method Sample Collections LC-MS
Validated at UF and UCD laboratories Linear LOQ = 25 pg/mL LOD ~10 pg/mL Sample Collections Stopped at 91 days Plasma concentrations below LOD for 2 successive collections Plasma concentrations less than LOQ at 77 days
35
Summary Stanozolol Aqueous suspension from compounding pharmacy
0.55 mg/kg intramuscular injection LOQ 25 pg/mL No plasma concentrations above 25 pg/mL after 49 days Substantial horse to horse variability
36
Summary Testosterone Aqueous suspension from compounding pharmacy
0.15 mg/kg subcutaneous injection LOQ 25 pg/mL No plasma concentrations above 25 pg/mL after 28 days Substantial horse to horse variability
37
Summary Boldenone Equipoise™brand of boldenone undecylenate in oil
1.1 mg/kg intramuscular injection LOQ 25 pg/mL Plasma concentrations above 25 pg/mL for about 140 days Horse to horse variability less than with other formulations
38
Summary Nandrolone Nandrolone decanoate in oil
0.55 mg/kg intramuscular injection LOQ 25 pg/mL No plasma concentrations above 25 pg/mL after 77 days Substantial horse to horse variability
39
Acknowledgements UC Davis Laboratory UF Racing Laboratory
UF Equine Performance Laboratory Bret Rice Jennifer Claflin Patrick Colahan, DVM Carly Brown Jennifer Pingel Stephanie Salas Kristy Smith Natalia Corredor Amber Davidson Allison Hreha Kevin LeBlanc Ted Broome, DVM UC Davis Laboratory Ben Moeller Scott Stanley, PhD Dan McKemie UF Racing Laboratory Nancy Szabo, PhD Carolyn Diaz Joy Guingab Katherine Wilding
40
Acknowledgements The authors would like to acknowledge the financial support for these projects from the Racing Medication and Testing Consortium, Inc. and the Division of Pari-Mutuel Wagering, Florida Department of Business and Professional Regulations.
Similar presentations
